The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- CYP2D6 genotype
研究概览
简要总结
The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.
详细描述
People with sickle cell disease require oral pain medications to manage an acute pain crisis. Sometimes these individuals fail to obtain adequate pain relief with the medications prescribed for outpatient use resulting in emergency room visits and hospital admissions. Subsequently, many patients are admitted to the hospital for pain management for a few days until the pain crisis resolves. The most common medications prescribed to sickle cell individuals for outpatient use include codeine and hydrocodone containing medications (i.e. Tylenol #3™, Vicodin™, Lortab™). These medications must be broken down in the body to make the active pain reliever (morphine or hydromorphone, respectively). Some individuals may not be able to break down these medications to the active pain reliever; therefore, these individuals will likely continue to experience pain unless they take other pain medications. We will determine whether genotype estimates the ability of CYP2D6 to break down codeine to the active pain reliever in individuals with sickle cell disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 years old
- •Sickle cell disease (HbSS)
- •Hydrocodone- or codeine-containing medications to manage an acute pain crisis in the past
排除标准
- •Renal dysfunction, serum creatinine (SCr) > 2.0 mg/dl
- •Hepatic dysfunction, AST, ALT or direct bilirubin > 3 x upper limit of normal (ULN)
- •Codeine allergy
- •Medications shown to induce or inhibit CYP2D6
- •Women who are pregnant or breast feeding
- •Unable to provide written, informed consent
结局指标
主要结局
CYP2D6 genotype
Plasma morphine and codeine concentrations
次要结局
- Disease severity
- Hospitalizations and admissions
